Elanco Animal Health Incorporated
ELANHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Elanco Animal Health Incorporated focuses on Drug Manufacturers - Specialty & Generic services and products. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company carries a $12.90B market cap, placing it firmly in the large-cap category. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Market Cap
$12.90B
Beta
1.69
P/E (TTM)
—
P/E (Fwd)
21.59
EPS (TTM)
$-0.50
EPS (Fwd)
$1.20
ROE
-3.8%
ROA
1.5%
Cash
$428.0M
Total Debt
$4.30B
Free CF
$692.1M
52W Change
74.8%
Annual Financials
Cash vs Debt
The company holds $428.0M in cash, though total debt stands at $4.30B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $692.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -3.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.41B (2022) to $4.71B (2025).
A beta of 1.69 means ELAN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing ELAN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.